Histogenics Corporation Cultura de la Empresa

Mr. Adam D. Gridley has been the Chief Executive Officer and President of Histogenics Corporation since May 12, 2014. Mr. Gridley served as Senior Vice President of Technical Operations at Merz North America, Inc. Mr. Gridley has over 20 years of proven results in the medical device, biotechnology and pharmaceutical industries. Mr. Gridley's career includes a combination of transactional and public markets experience as well as deep operational leadership and product development expertise. He is a strong interactive leader with significant experience in venture backed start-ups to large multinational pharmaceutical organizations, Mr. Gridley led several products through the development and regulatory approval phases into commercialization by building and leading functionally diverse global teams. His strong experience in manufacturing and quality operations has also facilitated the worldwide regulatory approvals of several diverse manufacturing sites. Focused on raising growth capital and enhancing shareholder value, Mr. Gridley has managed venture capital and public offerings and led many business development transactions with companies such as Boston Scientific, Wright Medical, Merck and Abgenix. During his time at Merz, he served as the global site head responsible for a variety of functions, including R&D, Manufacturing, Quality Operations, Finance and IT. Mr. Gridley served as Senior Vice President of Corporate Development at Merz Aesthetics, Inc. (alternate name BioForm Medical, Inc.) since September 2008. Mr. Gridley served as Vice President of Corporate Development at Merz Aesthetics, Inc. from July 2005 to September 2008 and also served as its Director for Corporate Development from April 2004 to July 2005 and Director of Market Development from September 2003 to April 2004. He served as Senior Vice President of Technical Operations at Merz Pharmaceuticals, LLC. His responsibilities included all business development, investor relations, strategic planning and R&D functions and he was part of the leadership team who led the Company's IPO and subsequent acquistion by Merz. From 1996 to June 2003, Mr. Gridley was with Gliatech, where he served as Director of Business Development. Mr. Gridley held several key strategic leadership roles in the orthopedics space during his career including Director of Business Development and Investor Relations at Gliatech Inc. Mr. Gridley has been a Director of Histogenics Corporation since May 12, 2014. Mr. Gridley holds a BS and an MBA from the University of Denver.

Dr. Donald D. Haut, also known as Don, Ph.D. has been Chief Business Officer at Histogenics Corporation since June 2017. Dr. Haut has been a Senior Advisor of Outcome Capital, LLC since October 14, 2015. He served as Managing Director of Haut Capital since 2014. He has a broad perspective in lifescience business from senior executive and Board positions in Strategy, M&A and General Management, with deep domain expertise across multiple disciplines in pharmaceutical, biotech and medical device industries. He served as Chief Business Officer at 480 Biomedical, Inc. until December 22, 2016. He served as Vice President of New Business Ventures at The Medicines Company, where he was responsible for leading its deal to license Alnylam's PCSK9 inhibitor. He served as Senior Vice President of Strategy and Business Development at Smith and Nephew's Advanced Surgical Devices Division, where he was responsible for all strategy development, M&A and licensing activities and also built & ran Smith & Nephew's Women's Health business. Dr. Haut also served with 3M, JSB Partners and McKinsey and Company. Dr. Haut serves as a Director of MiMecore Therapeutics, Arthrosurface, Inc. and Xiros, Ltd. He obtained his MBA at Washington University's Olin School of Business, his PhD in Molecular Biology at the University of Missouri-Columbia and his undergraduate degree at the College of Wooster.

Mr. Stephen R. Kennedy, also known as Steve, has been Executive Vice President and Chief Operating Officer of Histogenics Corporation since October 12, 2017. Mr. Kennedy served as the Chief Technology Officer of Histogenics Corporation since July 30, 2015 until October 12, 2017. Mr. Kennedy served as Senior Vice President of Technical Operations at Histogenics Corporation since August 2008. He served as the Senior Vice President of Manufacturing, Operations and Supply Chain at Histogenics Corporation since August 5, 2013. He served as Executive Vice President of Research and Development at Mascoma Corporation from May 2011 to August 2013. Mr. Kennedy has more than 30 years of experience in biological manufacturing and process development, including 18 years at Genzyme Corporation, where he had a strong history of company development and delivering process and organizational performance improvements resulting in increased profit. He served as Senior Vice President of Biologics Technical Operations at Genzyme Corporation from 2008 to October 2010. He developed cGMP biologics manufacturing operations at facilities in Belgium and France, oversaw Genzyme's gene therapy operation in San Diego and formed the global Biologics Operations organization. Before this, he developed the manufacturing process optimization organization that supported Genzyme's full range of products, including all biologics, Carticel??? and hyaluronic acid products, such as Seprafilm???. He focused on implementation and optimization of cell culture manufacturing technologies used in the production of flagship products at Genzyme, including Ceredase??? and Cerezyme???. Prior to Mascoma, Mr. Kennedy served as interim Executive Director of the Novartis/MIT Center for Continuous Manufacturing at Massachusetts Institute of Technology from October 2010 to May 2011. He managed process development at Genencor International in Helsinki, Finland from 1989 to 1992. He also spent time at Genencor in Finland and at Eastman Kodak, in Rochester, New York. He served as a Director at Xylitol Canada Inc. since April 24, 2012. Mr. Kennedy has an MBA from Boston University, an MS in Chemical Engineering/Biochemistry from the University of Rochester and a BS from the University of Michigan, Ann Arbor in Chemical Engineering/Biology.

Rich Vaillant serves as the CFO of Histogenics Corporation. Rich started at Histogenics Corporation in Jan of 2006. Rich currently resides in the Greater Boston Area.

Caroline Dugopolski serves as the VP of Technical Operations of Histogenics Corporation. Caroline started at Histogenics Corporation in Nov of 2015. Caroline currently resides in the Greater Boston Area.

Harry Shuman serves as the Vice President Finance of Histogenics Corporation. Harry started at Histogenics Corporation in Sep of 2015. Harry currently resides in the Greater Boston Area.

Stephen Kennedy serves as the EVP and Chief Operating Officer of Histogenics Corporation. Stephen started at Histogenics Corporation in Oct of 2017. Stephen currently resides in the Greater Boston Area.

Don Haut serves as the Chief Business Officer of Histogenics Corporation. Don started at Histogenics Corporation in Jun of 2017. Don currently resides in the Greater Boston Area.

Jonathan Lieber serves as the Chief Financial Officer of Histogenics Corporation. Jonathan started at Histogenics Corporation in Jun of 2015. Jonathan currently resides in the Greater Boston Area.